LBH589: Clinical Trials

47 trials of LBH589, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

33 completed, 10 terminated, 2 unknown, 1 recruiting. 47 Phase 1, 16 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 147Completed 33, Terminated 10, Unknown 2, Recruiting 1, Withdrawn 1
Phase 216Completed 10, Terminated 3, Unknown 2, Withdrawn 1

Follow LBH589: new trials by email Literature Review of LBH589 trials Research Report on LBH589

Trials (filtered) newest first · largest first

All 47 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
Abemaciclib, Abiraterone, Afatinib - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8
Phase 1TerminatedOHSU Knight Cancer Institute22020-04-012024-03-04
Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat
Panobinostat, Carfilzomib, Lenalidomide - Multiple Myeloma
Phase 1 / Phase 2WithdrawnH. Lee Moffitt Cancer Center and Research Institute2017-06-012017-04-25
A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat
PDR001, LCL161, Everolimus - Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma
Phase 1CompletedNovartis Pharmaceuticals2982016-10-142023-01-11
Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma
LBH589 - Glioma
Phase 1CompletedPediatric Brain Tumor Consortium532016-06-282024-04-25
Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Panobinostat, Fludarabine, Cytarabine - Acute Myeloid Leukemia, Myelodysplastic Syndrome
Phase 1TerminatedSt. Jude Children's Research Hospital192016-05-032018-11-14
Reducing the Residual Reservoir of HIV-1 Infected Cells in Patients Receiving Antiretroviral Therapy
Panobinostat, Pegylated Interferon-alpha2a - HIV Infection
Phase 1 / Phase 2CompletedMassachusetts General Hospital172016-05-012024-02-28
Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial)
Panobinostat, Ruxolitinib - Myelofibrosis
Phase 1 / Phase 2CompletedJohn Mascarenhas152013-01-012023-10-31
Safety and Effect of The HDAC Inhibitor Panobinostat on HIV-1 Expression in Patients on Suppressive HAART
Panobinostat - HIV Infection
Phase 1 / Phase 2CompletedUniversity of Aarhus152012-09-012014-02-25
A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) Patients
Panobinostat - Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML)
Phase 1CompletedNovartis Pharmaceuticals102012-08-012020-12-19
Panobinostat and Stereotactic Radiation Therapy in Treating Patients With Brain Tumors
Panobinostat, Stereotactic body radiation therapy, Quality-of-life assessment - Recurrent Glioma, High-grade Meningioma
Phase 1TerminatedSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University172012-05-012025-05-02
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome
Panobinostat, Cytarabine, Daunorubicin - Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome
Phase 1CompletedUniversity of California, San Francisco292012-01-012019-04-22
Study of the Combination of Panobinostat & Carfilzomib in Patients With Relapsed &/or Refractory Multiple Myeloma
Panobinostat, Carfilzomib, Dexamethasone - Multiple Myeloma
Phase 1CompletedEmory University322012-01-012019-01-16
Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis
panobinostat, ruxolitinib - Idiopathic Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis
Phase 1CompletedNovartis Pharmaceuticals612011-11-012021-06-25
Panobinostat and Carfilzomib in Treating Participants With Relapsed or Refractory Multiple Myeloma
Carfilzomib, Panobinostat - Non-Secretory Plasma Cell Myeloma, Plasmacytosis
Phase 1CompletedM.D. Anderson Cancer Center632011-07-282023-09-29
Phase I Study of Panobinostat + Bortezomib for Relapsed and/or Refractory Mantle Cell Lymphoma (MCL)
Panobinostat, Bortezomib - Mantle Cell Lymphoma
Phase 1CompletedAnand Jillella32011-04-012014-09-19
A Study Of Panobinostat In Children With Refractory Hematologic Malignancies
Panobinostat, Cytarabine - Lymphoblastic Leukemia, Acute, Childhood, Myelogenous Leukemia, Acute, Childhood
Phase 1CompletedTherapeutic Advances in Childhood Leukemia Consortium302011-03-012015-11-24
Phase I/II Study With Oral Panobinostat Maintenance Therapy Following Allogeneic Stem Cell Transplantation in Patients With High Risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)
Panobinostat - Myelodysplastic Syndrome, Acute Myeloid Leukemia
Phase 1 / Phase 2UnknownJohann Wolfgang Goethe University Hospital622011-01-012018-03-20
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
panobinostat - Sickle Cell Disease
Phase 1RecruitingAbdullah Kutlar182010-11-012026-01-09
Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML)
Panobinostat - Acute Myeloid Leukemia (AML)
Phase 1CompletedNovartis Pharmaceuticals462010-10-012020-12-19
Panobinostat and Fluorouracil Followed By Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer Who Did Not Respond to Previous Fluorouracil-Based Chemotherapy
panobinostat, fluorouracil, leucovorin calcium - Recurrent Colon Cancer, Recurrent Rectal Cancer
Phase 1TerminatedUniversity of Southern California72010-10-012015-05-27

Showing 20 of 47. Sign in to see all of them.

Conditions studied

Multiple Myeloma (9)  ·  Leukemia, Myeloid, Acute (7)  ·  Lymphoma (6)  ·  Hodgkin Disease (5)  ·  Lymphoma, Non-Hodgkin (5)  ·  Myelodysplastic Syndromes (5)  ·  Neoplasms (5)  ·  Prostatic Neoplasms (5)  ·  Leukemia (4)  ·  Primary Myelofibrosis (4)  ·  Breast Neoplasms (3)  ·  Glioma (3)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (3)  ·  Recurrence (3)  ·  Carcinoma, Non-Small-Cell Lung (2)

Sponsors

Novartis Pharmaceuticals (16)  ·  Emory University (2)  ·  M.D. Anderson Cancer Center (2)  ·  Roswell Park Cancer Institute (2)  ·  Abdullah Kutlar (1)  ·  Anand Jillella (1)  ·  City of Hope Medical Center (1)  ·  Dana-Farber Cancer Institute (1)  ·  H. Lee Moffitt Cancer Center and Research Institute (1)  ·  Johann Wolfgang Goethe University Hospital (1)  ·  John Mascarenhas (1)  ·  Massachusetts General Hospital (1)  ·  Mayo Clinic (1)  ·  NYU Langone Health (1)  ·  Novartis (1)

Countries

United States (39)  ·  Germany (6)  ·  Spain (4)  ·  Australia (3)  ·  Japan (3)  ·  Netherlands (3)  ·  United Kingdom (3)  ·  Canada (2)  ·  France (2)  ·  Italy (2)  ·  Sweden (2)  ·  Switzerland (2)  ·  Belgium (1)  ·  Denmark (1)  ·  Ireland (1)

Top investigators

Abdullah Kutlar, MD (1)  ·  Anand Jillella, MD (1)  ·  Anna Ferrari, MD (1)  ·  Charalambos Andreadis, M.D. (1)  ·  Daniel R Kuritzkes, MD (1)  ·  F. Stephen Hodi, MD (1)  ·  Francisco Hernandez, MD (1)  ·  Geoffrey Uy, M.D. (1)  ·  Gesine Bug, MD (1)  ·  Heinz-Josef Lenz (1)  ·  Howard A Burris, III, M.D. (1)  ·  James R. Berenson, MD (1)  ·  Jeffrey E. Rubnitz, MD,PhD (1)  ·  John Mascarenhas, MD (1)

Results publications

PMID 21706316, PMID 21964801, PMID 21984064, PMID 24135804, PMID 25062770, PMID 25253045, PMID 25572329, PMID 26423811, PMID 26696749, PMID 27740633, PMID 28905323, PMID 30610196, PMID 30830886, PMID 31541945, PMID 31654285, PMID 31778911, PMID 32338562, PMID 34482353, PMID 39863139

NIH funding

2009 (2), 2005 (1), 5UM1CA081457 (1), P30CA015083 (1), P30CA016672 (1), P30CA033572 (1)